StageMark
StageMark is a privately held Pittsburgh-based life-sciences company founded in 2004 that develops solutions for identifying and monitoring inflammatory diseases, led by co-founders Joseph Ahearn and Susan Manzi.
- Company typePrivate
- Founded2004
- HeadquartersPittsburgh, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
StageMark firmographics
Firmographics- Name
- StageMark
- Website
- https://stagemark.de
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- StageMark is a privately held Pittsburgh-based life-sciences company founded in 2004 that develops solutions for identifying and monitoring inflammatory diseases, led by co-founders Joseph Ahearn and Susan Manzi.
- Ownership category
- akta.pro rank
StageMark industry classification
Industry- Product category
- Inflammatory Disease Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)
- akta.pro secondary industry
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where StageMark is headquartered
LocationHeadquarters
- HQ city
- Pittsburgh
- HQ country
- United States
- HQ region
- North America
Markets served
StageMark business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
StageMark product offering
Product offeringCore offering
StageMark develops and markets solutions focused on the identification and monitoring of inflammatory diseases. The company's products are intended for clinical and research use in detecting and tracking inflammatory conditions. Specific product features, technologies, and customer-facing details are not documented in the available source data because the company's website returned a 500 Internal Server Error.
Differentiator
Problem solved
Functional benefit
Companies that use StageMark
Customer profileIdeal customer profiles1 record
StageMark technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
StageMark competitors and assessment
Company assessmentDirect peers
- Crescendo Bioscience: Crescendo developed multi-biomarker disease-activity tests for rheumatoid arthritis (Vectra DA), making it the closest direct analog to StageMark's inflammatory-disease identification and monitoring positioning; Crescendo was acquired by Myriad Genetics, reflecting the strategic value of this niche.
- Scipher Medicine: Scipher applies molecular/proteomic biomarker and network biology to autoimmune disease (e.g., PrismRA for RA non-response), directly overlapping StageMark's molecular-based inflammatory disease identification and monitoring thesis.
- Exagen: Exagen markets proprietary biomarker-based diagnostic tests (e.g., AVISE CTD) for autoimmune and inflammatory diseases, sharing StageMark's positioning around biomarker-led identification and monitoring in rheumatology.
Emerging players
- Quanterix: Quanterix provides ultra-sensitive single-molecule biomarker detection (Simoa) technology used in inflammatory and neurodegenerative disease research and diagnostics, comparable to StageMark in that biomarker detection underpins inflammatory disease applications.
- Singulex: Singulex commercializes high-sensitivity single-molecule counting biomarker technology used in inflammatory disease research, comparable to StageMark in deploying novel biomarker detection methods for inflammation applications.
- Protagen Diagnostics: Protagen develops multi-parameter biomarker-based diagnostic tests for autoimmune disease, overlapping with StageMark's inflammatory disease identification and monitoring focus via a biomarker-based IVD approach.
Broad incumbents
- Myriad Genetics: Myriad is a broad molecular diagnostics incumbent with autoimmunity/inflammatory disease tests acquired via Crescendo Bioscience; comparable in serving the same end-customers and reimbursement channels StageMark's tests would target.
- Labcorp: Labcorp is a major reference laboratory running inflammatory/autoimmune biomarker assays at scale, representing the incumbent channel against which any smaller diagnostics like StageMark must compete on test menus, coverage, and turn-around-time.
- Quest Diagnostics: Quest Diagnostics is a broad reference-laboratory incumbent offering inflammatory and autoimmune test panels across rheumatology, directly comparable to StageMark in serving rheumatologists and similar ordering physicians.
- Roche Diagnostics: Roche Diagnostics is a broad incumbent in clinical chemistry and immunoassay diagnostics, including inflammatory biomarkers (CRP, IL-6, etc.) consumed by rheumatology and primary care — defining the entrenched competitive context for StageMark.
Market position
Customer concentration
StageMark financial estimates
Financial estimateRevenue estimate
Valuation estimate
StageMark leadership team
Management profileNumber of profiles
Profiles2 records
StageMark funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
StageMark M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about StageMark
What does StageMark do?
StageMark develops and markets solutions focused on the identification and monitoring of inflammatory diseases. The company's products are intended for clinical and research use in detecting and tracking inflammatory conditions. Specific product features, technologies, and customer-facing details are not documented in the available source data because the company's website returned a 500 Internal Server Error.
When was StageMark founded?
StageMark was founded in 2004. It employs 11 to 50 people.
Where is StageMark based?
StageMark is headquartered in Pittsburgh, United States, in the North America region.
Who are StageMark's main competitors?
Direct peers on record are Crescendo Bioscience, Scipher Medicine and Exagen. Emerging players are Quanterix, Singulex and Protagen Diagnostics. Broad incumbents are Myriad Genetics, Labcorp, Quest Diagnostics and Roche Diagnostics.
Does StageMark have an API?
No public API is recorded for StageMark.
What industry is StageMark in?
StageMark's product category is Inflammatory Disease Diagnostics. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.